Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) · 2003
[A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Concha del Río Luz Elena, Arroyave Carlos M
Аннотация
BACKGROUND: Leukotrienes participate in certain biological activities such as contraction of human airway muscle, increased vascular permeability, chemotaxis and allergen-induced early and late responses.
OBJECTIVE: To evaluate the leukotriene antagonist montelukast in patients with atopic dermatitis unresponsive to traditional treatment.
METHODS: Eighteen children with atopic dermatitis were treated with 5 mg of chewable montelukast every 24 hs during a period of 24 weeks. Patient's history was utilized as a control for each individual. On each visit, every child was assessed by a single observer and objectively scored for disease extent and severity. In addition every parent filled a similar evaluation.
RESULTS: There was statistical improvement (p < 0.01) when values before and after treatment were analyzed, although no improvement was reported in five. No adverse reactions were reported.
CONCLUSION: Findings suggest that leukotriene antagonists can be used as an adjunct treatment on patients with atopic dermatitis that are refractory to traditional management.
OBJECTIVE: To evaluate the leukotriene antagonist montelukast in patients with atopic dermatitis unresponsive to traditional treatment.
METHODS: Eighteen children with atopic dermatitis were treated with 5 mg of chewable montelukast every 24 hs during a period of 24 weeks. Patient's history was utilized as a control for each individual. On each visit, every child was assessed by a single observer and objectively scored for disease extent and severity. In addition every parent filled a similar evaluation.
RESULTS: There was statistical improvement (p < 0.01) when values before and after treatment were analyzed, although no improvement was reported in five. No adverse reactions were reported.
CONCLUSION: Findings suggest that leukotriene antagonists can be used as an adjunct treatment on patients with atopic dermatitis that are refractory to traditional management.